On March 23, 2009, Oracle announced it agreed to acquire Relsys, a leading provider of drug safety, risk management and analytics applications for the health sciences industry. Relsys's best-in-class solutions support adverse event reporting, risk management and drug safety analysis for pharmaceutical, biotechnology, contract research organizations and medical device companies worldwide.
The combination of Relsys and Oracle's Health Sciences industry suite of products is expected to deliver the only suite of software applications that supports the end-to-end drug safety process across clinical development, post-market surveillance and patient care. Customers are expected to be able to identify safety issues earlier in the development process which can significantly reduce the costs associated with bringing drugs and devices to market. In addition, customers are expected to experience better insight and visibility across safety processes through an integrated and comprehensive view of data across adverse events, clinical studies and observational data.
Relsys customers and partners: Please use your existing contacts for support, professional services, and sales.
Join Oracle's most active, informed and satisfied customers participating in 450 users groups worldwide. The Oracle Clinical User Group (OCUG) is an international group of users of the Oracle Clinical software and related products. OCUG is a community for users to share best practices, discuss issues and identify new trends and provide input on products and services. The OCUG is pleased to welcome the Relsys community.